Analysts Reinforce Eli Lilly’s Bull Case on Strong 2026 Guide, GLP-1 Momentum

Fresh targets follow a robust outlook that has sharpened investor focus on execution.

Overview

Forbes/Trefis set a $1,350 price target, calling Lilly’s valuation very high but operational health very strong.
Deutsche Bank maintained a Buy rating with a $1,200 target on February 4, and Freedom Capital upgraded the stock to Buy with a $1,200 target on February 10.
Lilly guided 2026 revenue to $80–$83 billion with non-GAAP EPS of $33.50–$35.00, topping prior consensus.
Fourth-quarter 2025 revenue was about $19.3 billion, beating estimates on surging Mounjaro and Zepbound sales.
The company confirmed a U.S. launch of oral GLP-1 Orforg in Q2 2026, filed in Europe for Type 2 diabetes, flagged Medicare obesity coverage starting July 1, 2027, and agreed to acquire Orna Therapeutics for up to $2.4 billion.